Ref: New treatment options for EGFR mutated lung cancer ASCO
Adjuvant
1. ADAURA: osimertinib versus Gefitinib 3 yr adjuvant after R0 resection for stage IB-IIIA
5 yr OS 90% versus 80% for gefitinib. The benefit was more pronounced with stage II-IIIA NSCLC for DFS and OS benefit. 3 years of osimertinib doubles the chance of 5-year survival for patients with surgically resected EGFR-mutant NSCLC.
2. PACIFIC trial- chemo rad --> durva SOC; EGFR mutated pt did not benefit in subgroup analysis. Ongoing LAURA trial to see if consolidation osimertinib rather than durvalumab should be the new SOC for this subgroup. PFS was improved with osimertinib per press release.
3. FLAURA2 evaluated the addition of platinum-pemetrexed CT to osimertinib among patients with treatment-naïve advanced EGFR-mutated NSCLC.The median PFS was significantly improved with the addition of CT (25.5 months v 16.7 months, HR, 0.62 [95% CI, 0.49 to 0.79], P < .001), and ORR was also higher (83% v 76%).55 CNS PFS was improved in the combination arm
4. The phase III MARIPOSA trial compared amivantamab, an EGFR-MET bispecific antibody, plus lazertinib against osimertinib monotherapy, using investigator-assessed PFS as the primary end point. A third arm lazertinib monotherapy was included to assess the contribution of individual components. Amivantamab plus lazertinib reported a significantly longer PFS compared with osimertinib (23.7 months v 16.6 months, HR, 0.70 [95% CI, 0.58 to 0.85], P < .001) although ORR was similar (86% v 85%.
No comments:
Post a Comment